Tempus AI Shares Approach 1-Year Low as Cathie Wood’s ARK Increases Holdings While Selling Nvidia, Meta, and Other Tech Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Should l Buy TEM?
Source: stocktwits
ARK Investment Management's Activity: ARK Investment Management has purchased more shares of Tempus this week, investing nearly $28 million in the company despite its stock hitting a one-year low. The firm has also reduced its stakes in several large tech holdings.
Tempus' Recent Developments: Tempus has expanded its role in precision oncology research and clinical trial optimization, partnering with major pharmaceutical companies like Daiichi Sankyo to develop new cancer therapies using AI technology.
Market Sentiment and Stock Performance: Despite a recent decline in Tempus' stock, analysts maintain a positive outlook, with several firms reiterating 'buy' ratings and projecting significant revenue growth for the company in the coming years.
Retail Investor Sentiment: Retail sentiment towards Tempus has shifted to a more cautious stance, with some investors expressing optimism about future growth opportunities, while the stock has seen a significant decline over the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 55.810
Low
76.00
Averages
84.38
High
105.00
Current: 55.810
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempus AI Scheduled to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Tempus AI (TEM) is set to release its Q1 2023 earnings on May 5 after market close, with consensus EPS estimated at -$0.20 and revenue expected at $345.44 million, reflecting a 35.1% year-over-year growth, which could significantly impact investor confidence moving forward.
- Historical Performance Review: Over the past year, Tempus AI has beaten EPS and revenue estimates 75% of the time, indicating a stable performance in the market that may attract more investor interest in its future growth potential.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and six downward adjustments, while revenue estimates experienced four upward revisions and six downward changes, reflecting market uncertainty regarding the company's future performance, prompting investors to closely monitor the upcoming earnings report.
- Market Reaction Expectations: As the earnings report approaches, Tempus AI's stock price may be influenced by market sentiment, particularly given the rising investor interest in its AI model and high growth potential, which could lead to stock price volatility.
See More
Tempus AI (TEM) Q1 2026 Earnings Transcript
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $48.53 and a high of $92.65, with the latest trade at $76.22, indicating significant volatility over the past year and reflecting varying market perceptions of its portfolio.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess whether the current price is overvalued or undervalued, thus influencing investment decisions.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, providing flexibility that enhances ETF adaptability during market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as such liquidity changes can impact the individual components held within the ETFs.
See More
Tempus AI Named to TIME's 10 Most Influential Health Companies of 2026
- Industry Recognition: Tempus AI has been named one of TIME's 10 Most Influential Health and Life Science Companies of 2026, highlighting its innovation and impact in precision medicine, particularly in genomic testing and clinical analysis.
- FDA-Approved Testing Innovation: The xT CDx test, recognized by TIME, is a 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors, enhancing personalized treatment outcomes for patients and solidifying the company's market position.
- Strategic Acquisition Integration: Tempus' acquisition of Ambry Genetics has strengthened its capabilities in germline and pediatric areas, integrating comprehensive genomic data and enhancing its competitive edge within the precision medicine ecosystem.
- Partnership Expansion: Collaborations with AstraZeneca and Pathos AI aim to develop the largest multimodal foundation model in oncology, showcasing Tempus' strategic vision in advancing healthcare data intelligence and driving technological progress in the industry.
See More
Median Technologies Secures FDA 510(k) Clearance for eyonis® LCS, Accelerating U.S. Commercialization
- U.S. Market Access: Median Technologies has successfully secured FDA 510(k) clearance for eyonis® LCS, accelerating its commercialization efforts and expected to provide lung cancer screening services to approximately 14.5 million eligible individuals in the U.S., significantly enhancing the company's market share in cancer diagnostics.
- Reduction in Operating Loss: In 2025, Median Technologies achieved a 28% year-over-year reduction in operating loss, decreasing from €16.3 million in 2024 to €11.6 million in 2025, reflecting substantial improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Record Order Backlog: As of March 31, 2026, Median's iCRO order backlog reached a record €79.8 million, representing a 4.2% increase from €76.6 million in December 2025, providing strong revenue visibility for the coming years.
- Stable Cash Flow: As of March 31, 2026, the company reported cash and cash equivalents of €14.0 million, with the potential to raise up to €44.4 million through the exercise of 2025 warrants, ensuring stable cash flow through year-end 2026 to support the execution of its strategic priorities.
See More
Tempus and Predicta Launch Co-Branded Genomic Sequencing Assay
- Joint Launch of New Assay: Tempus AI and Predicta Biosciences announced the commercial expansion of the GenoPredicta™ genomic sequencing assay, aimed at comprehensive characterization of hematologic malignancies and measurable residual disease (MRD) monitoring, significantly enhancing diagnostic accuracy in clinical settings.
- Ultra-High Sensitivity: The GenoPredicta assay extracts deep genetic insights from as few as 50 tumor cells, achieving a sensitivity as low as one in a million, which expands testing eligibility to cases with low tumor burden, thereby increasing treatment opportunities for patients.
- Integrated Technology Advantage: By combining flow cytometry with whole-genome sequencing, the assay delivers 100% concordance between peripheral blood and bone marrow, sparing patients from invasive biopsies while providing researchers with deeper insights into disease biology.
- Accelerated Market Adoption: Predicta's CEO stated that this partnership with Tempus will accelerate market adoption and optimize the utility of clinical trials, further advancing the development of precision medicine and enabling smarter treatment decisions for physicians.
See More
Tempus AI Scheduled to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Tempus AI (TEM) is set to release its Q1 2023 earnings on May 5 after market close, with consensus EPS estimated at -$0.20 and revenue expected at $345.44 million, reflecting a 35.1% year-over-year growth, which could significantly impact investor confidence moving forward.
- Historical Performance Review: Over the past year, Tempus AI has beaten EPS and revenue estimates 75% of the time, indicating a stable performance in the market that may attract more investor interest in its future growth potential.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and six downward adjustments, while revenue estimates experienced four upward revisions and six downward changes, reflecting market uncertainty regarding the company's future performance, prompting investors to closely monitor the upcoming earnings report.
- Market Reaction Expectations: As the earnings report approaches, Tempus AI's stock price may be influenced by market sentiment, particularly given the rising investor interest in its AI model and high growth potential, which could lead to stock price volatility.
See More
Tempus AI (TEM) Q1 2026 Earnings Transcript
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $48.53 and a high of $92.65, with the latest trade at $76.22, indicating significant volatility over the past year and reflecting varying market perceptions of its portfolio.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess whether the current price is overvalued or undervalued, thus influencing investment decisions.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, providing flexibility that enhances ETF adaptability during market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as such liquidity changes can impact the individual components held within the ETFs.
See More
Tempus AI Named to TIME's 10 Most Influential Health Companies of 2026
- Industry Recognition: Tempus AI has been named one of TIME's 10 Most Influential Health and Life Science Companies of 2026, highlighting its innovation and impact in precision medicine, particularly in genomic testing and clinical analysis.
- FDA-Approved Testing Innovation: The xT CDx test, recognized by TIME, is a 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors, enhancing personalized treatment outcomes for patients and solidifying the company's market position.
- Strategic Acquisition Integration: Tempus' acquisition of Ambry Genetics has strengthened its capabilities in germline and pediatric areas, integrating comprehensive genomic data and enhancing its competitive edge within the precision medicine ecosystem.
- Partnership Expansion: Collaborations with AstraZeneca and Pathos AI aim to develop the largest multimodal foundation model in oncology, showcasing Tempus' strategic vision in advancing healthcare data intelligence and driving technological progress in the industry.
See More
Median Technologies Secures FDA 510(k) Clearance for eyonis® LCS, Accelerating U.S. Commercialization
- U.S. Market Access: Median Technologies has successfully secured FDA 510(k) clearance for eyonis® LCS, accelerating its commercialization efforts and expected to provide lung cancer screening services to approximately 14.5 million eligible individuals in the U.S., significantly enhancing the company's market share in cancer diagnostics.
- Reduction in Operating Loss: In 2025, Median Technologies achieved a 28% year-over-year reduction in operating loss, decreasing from €16.3 million in 2024 to €11.6 million in 2025, reflecting substantial improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Record Order Backlog: As of March 31, 2026, Median's iCRO order backlog reached a record €79.8 million, representing a 4.2% increase from €76.6 million in December 2025, providing strong revenue visibility for the coming years.
- Stable Cash Flow: As of March 31, 2026, the company reported cash and cash equivalents of €14.0 million, with the potential to raise up to €44.4 million through the exercise of 2025 warrants, ensuring stable cash flow through year-end 2026 to support the execution of its strategic priorities.
See More
Tempus and Predicta Launch Co-Branded Genomic Sequencing Assay
- Joint Launch of New Assay: Tempus AI and Predicta Biosciences announced the commercial expansion of the GenoPredicta™ genomic sequencing assay, aimed at comprehensive characterization of hematologic malignancies and measurable residual disease (MRD) monitoring, significantly enhancing diagnostic accuracy in clinical settings.
- Ultra-High Sensitivity: The GenoPredicta assay extracts deep genetic insights from as few as 50 tumor cells, achieving a sensitivity as low as one in a million, which expands testing eligibility to cases with low tumor burden, thereby increasing treatment opportunities for patients.
- Integrated Technology Advantage: By combining flow cytometry with whole-genome sequencing, the assay delivers 100% concordance between peripheral blood and bone marrow, sparing patients from invasive biopsies while providing researchers with deeper insights into disease biology.
- Accelerated Market Adoption: Predicta's CEO stated that this partnership with Tempus will accelerate market adoption and optimize the utility of clinical trials, further advancing the development of precision medicine and enabling smarter treatment decisions for physicians.
See More
